Autolus Therapeutics (AUTL) vs Editas Medicine (EDIT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Autolus Therapeutics (AUTL) has outperformed Editas Medicine (EDIT) over the past year, gaining 21.5% versus a loss of 30.0%. Over five years, AUTL leads with a -70.5% price change compared with -92.8% for EDIT. Autolus Therapeutics is the larger company by market cap ($481.8 million vs $422.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AUTL | EDIT |
|---|---|---|
| Share price | $1.81 | $2.75 |
| Market cap | $481.75M | $422.35M |
| 1-day change | +1.12% | +0.73% |
| YTD return | -9.05% | +34.15% |
| 1-year return | +21.48% | -30.03% |
| 5-year return | -70.52% | -92.77% |
| EPS (TTM) | $-1.06 | $-0.68 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.58 | $4.33 |
| 52-week low | $1.18 | $1.66 |
| Distance from 52-week high | -29.84% | -36.49% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +382.32% | +114.55% |
| Average volume | 2.10M | 2.48M |
| Shares outstanding | 266.16M | 153.58M |
| Employees | 752 | 87 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AUTL has outperformed EDIT by 51.5 percentage points over the past year.
About Autolus Therapeutics
AUTL stock →Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor.
Healthcare · Biotechnology · 752 employees
About Editas Medicine
EDIT stock →Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology.
Healthcare · Biotechnology · 87 employees
AUTL vs EDIT FAQ
Which is bigger, Autolus Therapeutics or Editas Medicine?
Autolus Therapeutics (AUTL) is larger, with a market capitalization of $481.75M compared with $422.35M for Editas Medicine (EDIT).
Which stock has performed better over the past year, AUTL or EDIT?
AUTL returned +21.48% over the past 12 months, compared with -30.03% for EDIT (price return, excluding dividends). Past performance does not predict future results.
Are Autolus Therapeutics and Editas Medicine in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.